A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 145-153

  Debata, Priya Ranjan ^a   Castellanos, Mario R ^a,b   Fata, Jimmie E ^a   Baggett, Sarah ^a   Rajupet, Sritha ^a,b   Szerszen, Anita ^a,b   Begum, Sultana ^a   Mata, Anita ^a   Murty, Vundavalli V ^c   Opitz, Lynne M ^b   Banerjee, Probal ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Cervical cancer; Curcumin; EGF receptor; Human papillomavirus; p53; Rb

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG; VACURIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CELL DEGENERATION; CELL VIABILITY; COLLOID; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MISCIBILITY; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; VAGINA EPITHELIUM; WART VIRUS;

ANIMALS; CELL SURVIVAL; CURCUMIN; FEMALE; HELA CELLS; HUMANS; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84884212000     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.005     Document Type: Article

References (41)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. L. Koutsky Epidemiology of genital human papillomavirus infection Am J Med 102 1997 3 8
3. National Cancer Institute Cancer trends progress report - update 2009/2010 Available at http://progressreport.cancer.gov/doc-detail.asp?pid= 1&did=2007&chid=72&coid=717&mid=#benefits [Accessed July 5, 2012]
4. R.S. Fowler Vulvar vestibulitis: response to hypocontactant vulvar therapy J Low Genit Tract Dis 4 2000 200 203
5. J.M. Crane Pregnancy outcome after loop electrosurgical excision procedure: a systematic review Obstet Gynecol 102 2003 1058 1062
6. B. Noehr, A. Jensen, K. Frederiksen, A. Tabor, and S.K. Kjaer Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period Am J Obstet Gynecol 201 33 2009 e1 e6
7. D.R. Pachman, D.L. Barton, A.C. Clayton, R.M. McGovern, J.A. Jeffries, and P.J. Novotny Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia Am J Obstet Gynecol 206 42 2012 e1 e7
8. M. Stanely Potential mechanisms for HPV vaccine-induced long-term protection Gynecol Oncol 118 2010 S2 S7
9. N. Dhillon, B.B. Aggarwal, R.A. Newman, R.A. Wolff, A.B. Kunnumakkara, and J.S. Abbruzzese Phase II trial of curcumin in patients with advanced pancreatic cancer Clin Cancer Res 14 2008 4491 4499
10. R.A. Sharma, S.A. Euden, S.L. Platton, D.N. Cooke, A. Shafayat, and H.R. Hewitt Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance Clin Cancer Res 10 2004 6847 6854
11. W.P. Steward, and A.J. Gescher Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research Mol Nutr Food Res 52 2008 1005 1009
12. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol Pharm 4 2007 807 818
13. A.N. Begum, M.R. Jones, G.P. Lim, T. Morihara, P. Kim, and D.D. Heath Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease J Pharmacol Exp Ther 326 2008 196 208
14. A. Strimpakos, and R.A. Sharma Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials Antioxid Redox Signal 10 2008 511 545
15. M. Kanai, K. Yoshimura, M. Asada, A. Imaizumi, C. Suzuki, and S. Marsumoto A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer Cancer Chemother Pharmacol 68 2011 157 164
16. A.L. Cheng, C.H. Hsu, J.K. Lin, M.M. Hsu, Y.F. Ho, and T.S. Shen Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions Anticancer Res 21 2001 2895 2900
17. D.M. Maher, M.C. Bell, E.A. O'Donnell, B.K. Gupta, M. Jaggi, and S.C. Chauhan Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7 Mol Carcinog 50 2011 47 57
18. R.K. Singh, D. Rai, D. Yadav, A. Bhargava, J. Balzarini, and E. De Clercq Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid Eur J Med Chem 45 2010 1078 1086
19. X. Si, Y. Wang, J. Wong, J. Zhang, B.M. McManus, and H. Luo Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication J Virol 81 2007 3142 3150
20. L.-Q. Jia, M. Osada, C. Ishioka, M. Gamo, S. Ikawa, and T. Suzuki Screening the p53 status of human cell lines using a yeast functional assay Mol Carcinog 19 1997 243 253
21. S. Forbes, J. Clements, E. Dawson, S. Bamford, T. Webb, and A. Dogan COSMIC 2005 Br J Cancer 94 2006 318 322
22. J.P.A. Baak, A.-J. Kruse, S.M. Garland, I. Skaland, E.A.M. Janssen, and S. Tabrizi Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions Am J Surg Pathol 29 2005 1062 1066
23. I.T. øvestad, E. Gudlaugsson, I. Skaland, A. Malpica, A.C. Munk, and E.A.M. Janssen The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2e3 J Clin Pathol 64 2011 303 307
24. I.T. øvestad, E. Gudlaugsson, I. Skaland, A. Malpica, A.-J. Kruse, and E.A.M. Janssen Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression Mod Pathol 23 2010 1231 1240
25. C.P. Harris, X.L. Lu, G. Narayan, B. Singh, and V.V.V.S. Murty Comprehensive molecular cytogenetic characterization of cervical cancer cell lines Genes Chromosomes Cancer 36 2003 233 241
26. L. Scotto, G. Narayan, S.V. Nadula, H. Arias-Pulido, S. Subramaniyam, and A. Schneider Identification of Copy number gain and overexpressed genes on chromosome Arm 20q by an integrative genomic approach in cervical cancer: potential role in progression Genes Chromosomes Cancer 47 2008 755 765
27. G. Narayan, L. Scotto, V. Neelakantan, S.H. Kottoor, A.H.Y. Wong, and S.-L. Loke Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer Genes Chromosomes Cancer 48 2009 983 992
28. P. Langone, P.R. Debata, S. Dolai, G.M. Curcio, J.D. Inigo, and K. Raja Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin Int J Cancer 131 2012 E569 E578
29. S. Purkayastha, A. Berliner, S.S. Fernando, B. Ranasinghe, I. Ray, and H. Tariq Curcumin blocks brain tumor formation Brain Res 1266C 2009 130 138
30. J.E. Fata, V. Chaudhary, and R. Khokha Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle Biol Reprod 65 2001 680 688
31. P. Langone, G.M. Curcio, K. Kashfi, S. Dolai, K. Raja, and P. Banerjee Drug targeting to eliminate breast and brain tumors Joint AACR and ACS meeting - chemistry in cancer research: the biological chemistry of inflammation as a cause of cancer. San Diego, CA 2011 [p. January 30, 2011 to February 2, 2011]
32. A. Bheda, K.E. Creek, and L. Pirisi Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes Oncogene 27 2008 4315 4323
33. C.-W. Chou, M.-S. Wu, W.-C. Huang, and C.-C. Chen HDAC inhibition decreases the expression of EGFR in colorectal cancer cells PLoS One 6 2011 e18087
34. Holte Pt, K. van Emelen, M. Janicot, P.C. Fong, J.S. de Bono, and J. Arts HDAC inhibition in cancer therapy: an increasingly intriguing tale of chemistry, biology and clinical benefit Top Med Chem 1 2007 293 331
35. S.J. Lee, C. Krauthauser, V. Maduskuie, P.T. Fawcett, J.M. Olson, and S.A. Rajasekaran Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo BMC Cancer 11 2011 1 13
36. V.A. Loyd Featured excipient: topical oil-in-water cream bases Int J Pharm Comp 6 2002 303 304
37. J. Doorbar Molecular biology of human papillomavirus infection and cervical cancer Clin Sci 110 2006 525 541
38. M.S. Moon, C.J. Lee, S.J. Um, J.S. Park, J.M. Yang, and E.S. Hwang Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells Gynecol Oncol 80 2001 168 175
39. Skp2 ubiquitin ligase J Virol 84 2010 437 444
40. L.M. Fahey, A.B. Raff, D.M. Da Silva, and W.M. Kast Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16 J Immunol 182 2009 2919 2928
41. M. van Seters, M. van Beurden, F.J. ten Kate, I. Beckmann, P.C. Ewing, and M.J. Eijkemnans Treatment of vulvar intraepithelial neoplasia with topical imiquimod N Engl J Med 358 2008 1465 1473